Altesa BioSciences

Executive Summary

Altesa BioSciences is a private biopharmaceutical company developing Vapendavir, a novel small-molecule antiviral targeting rhinovirus, the primary cause of acute exacerbations of chronic obstructive pulmonary disease (COPD). Unlike current treatments that manage symptoms after exacerbations occur, Vapendavir is designed to prevent exacerbations by inhibiting viral replication and associated airway inflammation. The company aims to disrupt the COPD treatment paradigm by addressing the upstream cause of exacerbations, potentially reducing hospitalizations, slowing disease progression, and improving quality of life for millions of patients worldwide. Currently in Phase 2 clinical development, Vapendavir has demonstrated promising safety and efficacy signals in earlier studies. The ongoing Phase 2 trial evaluates the drug in COPD patients with confirmed rhinovirus infection, with topline results expected by late 2026. If successful, Vapendavir could become the first targeted therapy for COPD exacerbations, a significant unmet medical need. However, risks include uncertain clinical outcomes, competitive landscape, and the need for additional funding to support Phase 3 trials and commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Topline Data Readout50% success
• H2 2026Partnership or Licensing Deal40% success
• H1 2027Series B Financing Round60% success